CASI Pharmaceuticals Future Growth
Future criteria checks 2/6
CASI Pharmaceuticals is forecast to grow earnings and revenue by 60.5% and 28.5% per annum respectively while EPS is expected to grow by 66% per annum.
Key information
60.5%
Earnings growth rate
66.0%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 28.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 May 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 110 | -6 | N/A | N/A | 1 |
12/31/2024 | 82 | -12 | N/A | N/A | 1 |
12/31/2023 | 43 | -26 | N/A | N/A | 1 |
3/31/2023 | 42 | -38 | N/A | N/A | N/A |
12/31/2022 | 43 | -41 | -27 | -21 | N/A |
9/30/2022 | 37 | -27 | -35 | -28 | N/A |
6/30/2022 | 35 | -32 | -35 | -25 | N/A |
3/31/2022 | 33 | -31 | -34 | -23 | N/A |
12/31/2021 | 30 | -37 | -42 | -27 | N/A |
9/30/2021 | 26 | -45 | -44 | -27 | N/A |
6/30/2021 | 22 | -52 | -54 | -30 | N/A |
3/31/2021 | 17 | -54 | -53 | -29 | N/A |
12/31/2020 | 15 | -48 | -43 | -26 | N/A |
9/30/2020 | 12 | -47 | -41 | -23 | N/A |
6/30/2020 | 10 | -40 | -29 | -21 | N/A |
3/31/2020 | 8 | -46 | -36 | -23 | N/A |
12/31/2019 | 4 | -46 | -37 | -23 | N/A |
9/30/2019 | 3 | -43 | -42 | -34 | N/A |
6/30/2019 | N/A | -42 | -42 | -33 | N/A |
3/31/2019 | N/A | -32 | -31 | -28 | N/A |
12/31/2018 | N/A | -27 | -50 | -29 | N/A |
9/30/2018 | N/A | -23 | -35 | -15 | N/A |
6/30/2018 | N/A | -16 | -32 | -12 | N/A |
3/31/2018 | N/A | -13 | -31 | -11 | N/A |
12/31/2017 | N/A | -11 | -7 | -6 | N/A |
9/30/2017 | N/A | -8 | -7 | -7 | N/A |
6/30/2017 | N/A | -8 | -7 | -7 | N/A |
3/31/2017 | N/A | -9 | -6 | -6 | N/A |
12/31/2016 | N/A | -9 | N/A | -6 | N/A |
9/30/2016 | N/A | -8 | N/A | -6 | N/A |
6/30/2016 | N/A | -8 | N/A | -6 | N/A |
3/31/2016 | 0 | -7 | N/A | -6 | N/A |
12/31/2015 | 0 | -7 | N/A | -6 | N/A |
9/30/2015 | 0 | -7 | N/A | -5 | N/A |
6/30/2015 | 0 | -27 | N/A | -5 | N/A |
3/31/2015 | 0 | -27 | N/A | -4 | N/A |
12/31/2014 | 0 | -26 | N/A | -4 | N/A |
9/30/2014 | N/A | -26 | N/A | -4 | N/A |
6/30/2014 | N/A | -6 | N/A | -4 | N/A |
3/31/2014 | N/A | -6 | N/A | -4 | N/A |
12/31/2013 | N/A | -6 | N/A | -3 | N/A |
9/30/2013 | 1 | -5 | N/A | -3 | N/A |
6/30/2013 | 1 | -5 | N/A | -3 | N/A |
3/31/2013 | 1 | -13 | N/A | -3 | N/A |
12/31/2012 | 1 | -15 | N/A | -2 | N/A |
9/30/2012 | 2 | -14 | N/A | -2 | N/A |
6/30/2012 | 2 | -14 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YZ3 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YZ3 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YZ3 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YZ3's revenue (28.5% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: YZ3's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YZ3's Return on Equity is forecast to be high in 3 years time